SCHEMBL6722071

SCHEMBL6722071

Cc1cncc(-c2[nH]c(C(F)F)nc2-c2ccc(S(C)(=O)=O)c(F)c2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 7/20 0.37
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
PTGS2 P35354 3/20 0.35
ALOX5 P09917 3/20 0.35
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.34
KMT2A Q03164 1/20 0.34
TYK2 P29597 4/20 0.34
PTGS1 P23219 1/20 0.34
CYP3A4 P08684 2/20 0.34
CSNK1D P48730 3/20 0.33
CSNK1E P49674 3/20 0.33
CSNK1A1 P48729 1/20 0.33
MAPK11 Q15759 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6718410 0.90 PIK3CD (0.39) MAPK14PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL6723415 0.88 ALDH1A1 (0.43) MAPK14PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL6725894 0.86 MAPK14 (0.47) MAPK14PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL6731970 0.86 PTGS2 (0.33) MAPK14CYP11B1CYP11B2PTGS2ALOX5
SCHEMBL6733700 0.85 PTGS2 (0.33) PTGS2ALOX5ALDH1A1KDM4ELMNA
SCHEMBL6722608 0.85 PTGS2 (0.40) MAPK14PTGS2ALOX5ALDH1A1LMNA
SCHEMBL6729827 0.85 PIK3CD (0.38) MAPK14PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL6730668 0.85 PTGS1 (0.40) MAPK14PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL6723200 0.85 PTGS1 (0.48) MAPK14PTGS2ALOX5ALDH1A1PTGS1
SCHEMBL6719062 0.85 PTGS2 (0.38) MAPK14PIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 MAPK14 2499/4885PIK3CD 4290/4885PIK3CA 3770/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 MAPK14 2354/4885PIK3CD 4382/4885PIK3CA 3934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.